Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer.

A great deal of attention has been focused on the antitumor effects of anti-MUC1 humoral and cellular responses. We examined whether anti-MUC1 antibody is present in patients with lung cancer, and evaluated its prognostic value. Serum was obtained from 30 patients with nonresectable, non-small cell lung cancer (NSCLC) and 60 healthy volunteers. The presence of anti-MUC1 antibody was determined by enzyme-linked immunosorbent assay. The patients were observed for a median follow-up time of 54.0 mo. Overall survival was estimated by the Kaplan-Meier method. Multivariate analyses were performed using the Cox proportional hazards regression model. Anti-KL-6/MUC1 antibody levels of the patients were significantly lower than those of normal individuals (p < 0.001). One-year survival rate of patients with high concentrations of anti-KL-6/MUC1 antibody was significantly higher than that of patients with low levels of anti-KL-6/MUC1 antibody (90.9% versus 21.1%, p < 0.001). Anti-KL-6/MUC1 antibody status was most strongly correlated with mortality, followed by lymph node status and albumin levels, whereas sex, serum lactate dehydrogenase (LDH), and carcinoembryonic antigen (CEA) levels, and metastasis status did not correlate with mortality. These preliminary results indicate that the degree of decrease in antibody level may be associated with a patient's prognosis.

[1]  L. Frati,et al.  Human B-cell immune response to the polymorphic epithelial mucin. , 1993, Cancer research.

[2]  S. Hakomori,et al.  Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. , 1992, The New England journal of medicine.

[3]  H. Satoh,et al.  Predictive value of preoperative serum sialyl Lewis X-i antigen levels in non-small cell lung cancer. , 1998, Anticancer research.

[4]  N. Kohno,et al.  KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts. , 1997, American journal of respiratory cell and molecular biology.

[5]  C. Angeletti,et al.  Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  R. Dahiya,et al.  Heterogeneity of mucin gene expression in normal and neoplastic tissues. , 1993, Cancer research.

[7]  T. Kipps,et al.  Structure-function studies on a polyreactive (natural) autoantibody. Polyreactivity is dependent on somatically generated sequences in the third complementarity-determining region of the antibody heavy chain. , 1994, Journal of immunology.

[8]  M. Reddish,et al.  Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 , 1998, Nature Medicine.

[9]  P. Kenemans,et al.  Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. , 1995, British Journal of Cancer.

[10]  N. Kohno,et al.  Detection of a circulating tumor-associated antigen with a murine monoclonal antibody, LISA 101, selected by reversed indirect enzyme-linked immunosorbent assay. , 1989, Cancer research.

[11]  R. Metzgar,et al.  Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. , 1994, Cancer research.

[12]  N. Peat,et al.  Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. , 1992, Cancer research.

[13]  S. Avrameas,et al.  Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. , 1991, Immunology today.

[14]  W. Gilks,et al.  Third international workshop on lung tumor and differentiation antigens: Overview of the results of the central data analysis , 1994, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[15]  N. Kohno,et al.  Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. , 1998, Cancer research.

[16]  N. Kohno,et al.  New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. , 1989, Chest.

[17]  G. Catalano,et al.  Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. , 1998, Oncology reports.

[18]  H. Stein,et al.  Carbohydrate Recognition on MUC1‐Expressing Targets Enhances Cytotoxicity of a T Cell Subpopulation , 1997, Scandinavian journal of immunology.

[19]  V. Apostolopoulos,et al.  Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. , 1997, The Journal of clinical investigation.

[20]  N. Kohno,et al.  A New Serum Tumor Marker, CAM 123‐6, Highly Specific to Pulmonary Adenocarcinoma , 1994, Japanese journal of cancer research : Gann.

[21]  M. McGuckin,et al.  Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women , 1998, Cancer Immunology, Immunotherapy.

[22]  J. Bártková,et al.  A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM‐3 is selectively exposed in a range of primary carcinomas , 1989, International journal of cancer.

[23]  S. Meijer,et al.  Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. , 1996, European journal of cancer.

[24]  O. Nilsson,et al.  Summary Report on the ISOBM TD-4 Workshop: Analysis of 56 Monoclonal Antibodies against the MUC1 Mucin , 1997, Tumor Biology.

[25]  M. Reddish,et al.  Anti‐MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide , 1998, International journal of cancer.

[26]  A. Harris,et al.  MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. , 1998, Journal of clinical pathology.

[27]  I. Cohen,et al.  Autoimmunity, microbial immunity and the immunological homunculus. , 1991, Immunology today.

[28]  N. Kohno,et al.  Difference in sero‐diagnostic values among KL‐6‐associated mucins classified as cluster 9 , 1994, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[29]  J. Taylor‐Papadimitriou,et al.  Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[30]  W. Bodmer,et al.  Monoclonal antibodies to epithelium‐specific components of the human milk fat globule membrane: Production and reaction with cells in culture , 1981, International journal of cancer.

[31]  M. Volm,et al.  Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. , 1997, British Journal of Cancer.

[32]  N. Kohno,et al.  Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. , 1988, Japanese journal of clinical oncology.

[33]  N. Kohno,et al.  Immunoreactive MUC1 Expression at the Deepest Invasive Portion Correlates with Prognosis of Colorectal Cancer , 1998, Oncology.